Source: International Congress 2016 – IPF treatment II
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Bruno Crestani (Paris, France), Bruno Crestani, Manuel Quaresma, Mitchell Kaye, Wibke Stansen, Susanne Stowasser, Michael Kreuter. Long-term treatment with nintedanib in patients with IPF: An update from INPULSIS®-ON. Eur Respir J 2016; 48: Suppl. 60, 4960

Member's Comments

No comment yet.

Related content which might interest you: Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Long-term safety of combination therapy with nintedanib and pirfenidone in Japanese patients with IPF Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease III Year: 2013 Pirfenidone treatment in idiopathic pulmonary fibrosis: An Italian case series Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Effect of baseline statin use on benefit of nintedanib Source: International Congress 2016 – IPF treatment II Year: 2016 Clinical experience with nintedanib for the treatment of IPF in 80 cases Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Relationship between nintedanib exposure and adverse events in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF treatment II Year: 2016 Initial clinical experience with nintedanib for treatment of idiopathic pulmonary fibrosis (IPF): About 20 cases Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Effect of baseline composite physiologic index on benefit of nintedanib in IPF Source: International Congress 2016 – IPF treatment I Year: 2016 Efficacy of pirfenidone in idiopathic pulmonary fibrosis: A single center experience Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Pirfenidone post-authorization safety registry (PASSPORT) update Source: International Congress 2015 – Treatment of IPF Year: 2015 Treatment of severe pulmonary hypertension in patients with interstitial lung disease: Results in 72 patients from the “HYPID” prospective study Source: Annual Congress 2013 –Pulmonary circulation: treatment Year: 2013 Long term efficacy of pirfenidone therapy in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2014 – ILDs 3 Year: 2014 LATE-BREAKING ABSTRACT: Detrimental effects of medically indicated oral anticoagulation on survival in idiopathic pulmonary fibrosis (IPF) Source: International Congress 2015 – Latest developments in clinical studies in acute and chronic lung diseases Year: 2015 Pirfenidone in patients with advanced idiopathic pulmonary fibrosis: First experience Source: International Congress 2016 – IPF: from pathogenesis to treatment I Year: 2016 Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients Source: International Congress 2016 – IPF pathogenesis Year: 2016 Predictors of response to pirfenidone treatment in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – IPF treatment II Year: 2016 Negative outcome of prednisone in possible idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF clinical Year: 2016 Inspiration plus: baseline characteristics of the canadian registry for IPF patients on pirfenidone Source: International Congress 2016 – Orphan diseases II Year: 2016 Clinical efficacy of pirfenidone in patients with severe fibrosing interstitial pneumonia Source: International Congress 2015 – Treatment of IPF Year: 2015